Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glas… Read more
Market Cap & Net Worth: Genomic Vision Société Anonyme (G09)
Genomic Vision Société Anonyme (F:G09) has a market capitalization of $417.14 Billion (€406.38 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #36767 globally and #4581 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genomic Vision Société Anonyme's stock price €1055.25 by its total outstanding shares 385105984 (385.11 Million).
Genomic Vision Société Anonyme Market Cap History: 2015 to 2026
Genomic Vision Société Anonyme's market capitalization history from 2015 to 2026. Data shows growth from $3.42 Billion to $417.14 Billion (56.68% CAGR).
Genomic Vision Société Anonyme Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genomic Vision Société Anonyme's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.05x
Genomic Vision Société Anonyme's market cap is 5.05 times its annual revenue
0.68x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.42 Billion | $4.27 Million | -$4.34 Million | 801.33x | N/A |
| 2016 | $1.76 Billion | $3.04 Million | -$8.61 Million | 580.38x | N/A |
| 2017 | $1.34 Billion | $3.57 Million | -$9.07 Million | 374.83x | N/A |
| 2018 | $101.99 Million | $1.90 Million | -$6.90 Million | 53.56x | N/A |
| 2019 | $114.24 Million | $2.24 Million | -$4.61 Million | 51.02x | N/A |
| 2020 | $306.75 Million | $1.30 Million | -$5.18 Million | 236.51x | N/A |
| 2021 | $79.46 Million | $1.41 Million | -$5.00 Million | 56.23x | N/A |
| 2022 | $7.47 Million | $1.48 Million | -$6.79 Million | 5.05x | N/A |
Competitor Companies of G09 by Market Capitalization
Companies near Genomic Vision Société Anonyme in the global market cap rankings as of March 18, 2026.
Key companies related to Genomic Vision Société Anonyme by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Genomic Vision Société Anonyme Historical Marketcap From 2015 to 2026
Between 2015 and today, Genomic Vision Société Anonyme's market cap moved from $3.42 Billion to $ 417.14 Billion, with a yearly change of 56.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €417.14 Billion | +9.52% |
| 2025 | €380.90 Billion | +35.08% |
| 2024 | €281.98 Billion | +41960488.24% |
| 2023 | €672.01K | -91.01% |
| 2022 | €7.47 Million | -90.60% |
| 2021 | €79.46 Million | -74.10% |
| 2020 | €306.75 Million | +168.51% |
| 2019 | €114.24 Million | +12.02% |
| 2018 | €101.99 Million | -92.38% |
| 2017 | €1.34 Billion | -23.99% |
| 2016 | €1.76 Billion | -48.57% |
| 2015 | €3.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Genomic Vision Société Anonyme was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $417.14 Billion USD |
| MoneyControl | $417.14 Billion USD |
| MarketWatch | $417.14 Billion USD |
| marketcap.company | $417.14 Billion USD |
| Reuters | $417.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.